| NoAF Group, n = 86 | ShortAF Group, n = 24 | P value |
---|---|---|---|
Mean age, yearsa | 66 ± 10 | 71 ± 9 | 0.033 |
Men, n (%) | 55 (64) | 15 (63) | 1.000 |
BMIa | 31 ± 23 | 30 ± 6 | 0.761 |
P-wave duration, msa | 136 ± 15 | 143 ± 18 | 0.232 |
Patients with P-wave duration > 120 ms, n (%) | 70 (81) | 20 (83) | 0.451 |
PR-interval, msa | 175 ± 29 | 158 ± 22 | 0.007 |
P-wave terminal force in lead V1, mm x msa | 23 ± 24 | 28 ± 35 | 0.394 |
QRS duration, msa | 100 ± 18 | 100 ± 15 | 0.962 |
QTc, msa | 430 ± 28 | 430 ± 28 | 1.000 |
PW morphology | Â | Â | 0.570 |
X(+)Y(+)Z(-), n (%) | 16 (20) | 3 (14) | Â |
X(+)Y(+)Z(-/+), n (%) | 45 (56) | 15 (71) | Â |
IAB or X(+)Y(+/-), n (%) | 2 (3) | 0 (0) | Â |
X(+)Y(+)Z(+), n (%) | 18 (22) | 3 (14) | Â |
Left atrium volume index, ml/m2 | 32 ± 10 | 42 ± 15 | 0.007 |
EF, % | 58 ± 12 | 56 ± 13 | 0.499 |
Left ventricular S, mma | 33 ± 9 | 35 ± 8 | 0.496 |
Left ventricular D, mma | 49 ± 7 | 50 ± 6 | 0.679 |
Right atrial pressure, mmHga | 6 ± 2 | 6 ± 2 | 0.498 |
Right ventricular systolic pressure, mmHga | 33 ± 11 | 36 ± 7 | 0.490 |
Diabetes, n (%) | 17 (20) | 1 (4) | 0.115 |
Hypertension, n (%) | 66 (76) | 18 (75) | 1.000 |
Ischemic heart disease, n (%) | 17 (20) | 4 (17) | 1.000 |
Cardiac failure, n (%) | 4 (5) | 2 (9) | 0.604 |
CHADS2 scorea | 3.2 ± 0.9 | 3.2 ± 0.9 | 0.996 |
CHA2DS2-VASc scorea | 4.3 ± 1.5 | 4.5 ± 1.4 | 0.579 |